Serum Hsp70 Level in Patients With Endometrial Cancer With and Without Diabetes Publisher Pubmed



Heidari F¹ ; Rabizadeh S¹ ; Sadat Salehi S¹ ; Akhavan S² ; Khaloo P¹ ; Alemi H¹ ; Mirmiranpour H¹ ; Esteghamati A¹ ; Nakhjavani M¹ Show Affiliations
Source: Gynecological Endocrinology Published:2020

Abstract

Diabetes mellitus (DM) is associated with an increased risk of endometrial carcinoma (EC). Heat shock proteins have a role in the modulation of both diseases. The aim of this study was to investigate extracellular HSP70 (eHSP70) level alternations in patients with two different types of EC (endometrioid and non-endometrioid) with and without type 2 diabetes. In a case–control study, 88 participants were enrolled in four groups including: 18 EC patients with DM, 19 EC patients without DM, 29 patients with DM, and 22 healthy individuals. Blood samples were taken before surgery in cancer patients. Estradiol, eHSP70, sex hormone-binding globulin (SHBG), FBS, and HbA1c were assessed. Serum HSP70 level was higher in patients with diabetes (52.24 ± 14.2 ng/ml) compared to healthy controls (39.04 ± 6.96) (p <.05). It was lower in EC (26.05 ± 12.28) compared to healthy controls (39.04 ± 6.96) (p <.05). eHSP70 was also lower in endometrioid-type carcinoma (22.57 ± 11) compared to non-endometrioid type (31.55 ± 12.38) (p <.05). Further analysis showed increased levels of eHSP70 in patients having both endometrioid-type carcinoma and diabetes (27.23 ± 11.41) compared to the same patients without DM (17.08 ± 7.78) (p <.05). Presence of diabetes in patients with endometrioid type carcinoma resulted in an increase in eHSP70 approaching the level of eHSP70 in patients with non-endometrioid histology. © 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group.